“ID Biomedical Announces Strong Immunogenicity Data From Phase II Trials of FluINsure”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

FluINsure, ID Biomedical Corp.’s intranasal, non-live influenza vaccine, reportedly has demonstrated “strong” immunogenicity in various phase II clinical trials. According to the company, 252 healthy adult volunteers have signed up for the clinical trials, with 175 receiving FluINsure and 77 getting placebos. The researchers measured the immunogenicity of the vaccine using serum hemagglutination-inhibiting (HAI) antibody titers and the exact amount of nasal secretory IgA antibodies found in the influenza viruses included in the vaccine. ID Biomedical asserted that both the one- and two-dose regimens generated serum HAI and nasal antibody responses that were stronger than the data developed with the live cold-adapted intranasal influenza vaccine.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.